Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Vertex Pharmaceuticals Inc. sell Canaccord Genuity Group Inc.

Start price
€401.90
24.01.24 / 50%
Target price
€346.79
24.01.25
Performance (%)
4.37%
End price
€419.45
25.01.25
Summary
This prediction ended on 25.01.25 with a price of €419.45. The SELL prediction by Canaccord_Genuity_Gr shows the price for Vertex Pharmaceuticals Inc. slightly increased by 4.37% during the runtime of the prediction. Canaccord_Genuity_Gr has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Vertex Pharmaceuticals Inc. 0.763% 0.763% -14.391%
iShares Core DAX® -1.212% 1.925% 17.589%
iShares Nasdaq 100 -4.714% -1.810% 0.450%
iShares Nikkei 225® -2.976% -2.660% 10.156%
iShares S&P 500 -2.744% -0.448% 0.320%

Comments by Canaccord_Genuity_Gr for this prediction

In the thread Trading Vertex Pharmaceuticals Inc.
Prediction Sell
Perf. (%) 4.37%
Target price 346.785
Change
Ends at 24.01.25

Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten

In the thread Vertex Pharmaceuticals Inc. diskutieren
Prediction Sell
Perf. (%) 4.37%
Target price 346.785
Change
Ends at 24.01.25

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "sell" rating. They now have a $379.00 price target on the stock, up previously from $332.00.
Ratings data for VRTX provided by MarketBeat